Davies T A, Pankuch G A, Dewasse B E, Jacobs M R, Appelbaum P C
Department of Pathology (Clinical Microbiology), Hershey Medical Center, Hershey, Pennsylvania 17033, USA.
Antimicrob Agents Chemother. 1999 May;43(5):1177-82. doi: 10.1128/AAC.43.5.1177.
The ability of 50 sequential subcultures in subinhibitory concentrations of ciprofloxacin, levofloxacin, grepafloxacin, sparfloxacin, trovafloxacin, and amoxicillin-clavulanate to select for resistance was studied for six penicillin-susceptible and four penicillin-intermediate pneumococci. Subculturing in ciprofloxacin, grepafloxacin, levofloxacin, and sparfloxacin led to selection of mutants requiring increased MICs for all 10 strains, with MICs rising from (i) 0.5 to 4.0 to (ii) 4.0 to 32.0 microgram/ml after 7 to 12 passages for ciprofloxacin, from (i) 0.06 to 0.25 to (ii) 0.5 to 8.0 microgram/ml after 5 to 23 passages for grepafloxacin, from (i) 0.5 to 1.0 to (ii) 4.0 to 64 microgram/ml after 14 to 49 passages for levofloxacin, and from (i) 0.125 to 0.25 to (ii) 1.0 to 16.0 microgram/ml after 8 to 26 passages for sparfloxacin. Subculturing in trovafloxacin led to increased MICs for eight strains, with MICs rising from (i) 0.06 to 0.125 to (ii) 0.5 to 8.0 microgram/ml after 6 to 28 passages. Subculturing in amoxicillin-clavulanate led to raised MICs for only one strain, with the MIC rising from 0.015 to 0. 125 microgram/ml after 24 passages. Double mutations in both ParC and GyrA led to high-level quinolone resistance when ParC mutations were at S79. Trovafloxacin MICs were 1 to 2 microgram/ml in double mutants with ParC mutations at positions other than S79 (e.g., D83). Mutations in ParE (at D435, R447, and E474) and GyrB (at S405, D406, and D435) were found in four and six mutants, respectively. In the presence of reserpine, 29 mutants had lower ciprofloxacin MICs (2 to 16 times lower), 8 mutants had lower levofloxacin MICs (2 times), and one mutant had a lower trovafloxacin MIC (2 times), suggesting the involvement of an efflux mechanism. In contrast to the case for quinolones, subculturing in the presence of amoxicillin-clavulanate did not select for resistance to this drug.
研究了在环丙沙星、左氧氟沙星、格帕沙星、司帕沙星、曲伐沙星和阿莫西林-克拉维酸的亚抑菌浓度下,对6株青霉素敏感和4株青霉素中介的肺炎球菌进行50次连续传代培养以筛选耐药性的能力。在环丙沙星、格帕沙星、左氧氟沙星和司帕沙星中传代培养导致所有10株菌株均筛选出需要更高最低抑菌浓度(MIC)的突变体,环丙沙星在7至12次传代后,MIC从(i)0.5至4.0微克/毫升升至(ii)4.0至32.0微克/毫升;格帕沙星在5至23次传代后,MIC从(i)0.06至0.25微克/毫升升至(ii)0.5至8.0微克/毫升;左氧氟沙星在14至49次传代后,MIC从(i)0.5至1.0微克/毫升升至(ii)4.0至64微克/毫升;司帕沙星在8至26次传代后,MIC从(i)0.125至0.25微克/毫升升至(ii)1.0至16.0微克/毫升。在曲伐沙星中传代培养导致8株菌株的MIC升高,在6至28次传代后,MIC从(i)0.06至0.125微克/毫升升至(ii)0.5至8.0微克/毫升。在阿莫西林-克拉维酸中传代培养仅导致1株菌株的MIC升高,在24次传代后,MIC从0.015微克/毫升升至0.125微克/毫升。当ParC突变位于S79时,ParC和GyrA中的双突变导致高水平喹诺酮耐药。在ParC突变位于S79以外位置(如D83)的双突变体中,曲伐沙星的MIC为1至2微克/毫升。在4个和6个突变体中分别发现了ParE(位于D435、R447和E474)和GyrB(位于S405、D406和D435)的突变。在利血平存在的情况下,29个突变体的环丙沙星MIC较低(低2至16倍),8个突变体的左氧氟沙星MIC较低(低2倍),1个突变体的曲伐沙星MIC较低(低2倍),提示存在外排机制。与喹诺酮类药物的情况相反,在阿莫西林-克拉维酸存在下传代培养未筛选出对该药物的耐药性。